FIELD: medicine.
SUBSTANCE: disclosed is a composition for treating a lysosomal storage disease, comprising a recombinant glycoprotein, which is human β-glucuronidase and having a degree of sialylation of about 1.1 mol/mol.
EFFECT: invention provides high content of sialic acid in the glycoprotein for pharmacological application.
9 cl, 7 dwg, 6 tbl, 3 ex
Authors
Dates
2019-05-24—Published
2015-03-05—Filed